Reasons for testing women for genital Chlamydia trachomatis infection in the Calgary region

Canadian Journal of Infectious Diseases

Volumn 14, Issue 1, 2003, Pages 35-40

  Church, Deirdre L ^a,b,c   Zentner, Ali ^b   Semeniuk, Heather ^a   Henderson, Elizabeth ^a   Read, Ron ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b Laboratory Medicine   (Canada)

^c CALGARY LABORATORY SERVICES   (Canada)

Author keywords

Chlaymdia trachomatis; Genital infection; Screening; Women

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENITAL TRACT INFECTION; GYNECOLOGICAL EXAMINATION; HEALTH SERVICE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASS SCREENING; NUCLEIC ACID AMPLIFICATION; PAPANICOLAOU TEST; PATIENT CARE; RISK FACTOR; SCREENING TEST; URINALYSIS; UTERINE CERVIX CYTOLOGY; UTERINE ENDOCERVIX;

EID: 0037239915     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/682345     Document Type: Article

References (25)

1. Black CM. Current methods of laboratory diagnosis of Chlamydia trachomatis infection. Clin Microbiol Rev 1997;10:160-84.
2. Stamm WE. Chlamydia trachomatis infections: progress and problems. J Infect Dis 1999;179(Suppl 2):S380-3.
3. Peeling RW, King L. Sexually transmitted diseases: Impact of molecular laboratory diagnostic methods on disease control and prevention. Can J Infect Dis 1999;10:387-90.
4. Health Canada. Notifiable Diseases Summary. Can Commun Dis Rep 1999;25:174.
5. Davies HD, Wang EE. Periodic Health Examination, 1996 update: 2. Screening for chlamydial infections. CMAJ 1996;154:1631-44.
6. Cates W Jr, Wasserheit JN. Genital chlamydial infections: epidemiology and reproductive sequelae. Am J Obstet Gynecol 1991;164:1771-81.
7. Pearlman MD, McNeeley SG. A review of the microbiology, immunology, and clinical manifestations of Chlamydia trachomatis infections. Obstet Gynecol Surv 1992;47:448-61.
8. Scoles D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996;334:1362-6.
9. Wasserheit JW. Epidemiological synergy: interrelationships between HIV infection and other STDs. In: Chen LC, Amor JS, Segal SJ, eds. AIDS and Women's Reproductive Health. New York: Plenum Press, 1991:7-72.
10. Gully P, Rwetsiba DK. Chlamydial infection in Canada. CMAJ 1992;147:893-6.
11. Laboratory Centre for Disease Control Expert Working Group on Canadian Guidelines for Sexually Transmitted Diseases. Canadian STD Guidelines, 1998. Ottawa: Minister of Public Works and Government Services Canada, 1998.
12. Weyman D, Lansing AR. Screening guidelines for Chlamydia trachomatis infection. Can Fam Physician 1995;41:228-36.
13. Semeniuk H, Zentner A, Read R, Church DL. Evaluation of sequential testing strategies using non-amplified and amplified methods for detection of Chlamydia trachomatis in endocervical and urine specimens from women. Diagn Micro Inf Dis 2002;42:43-51.
14. Ferraro DV, Meyers HN, Schultz DE, Willis SA. Performance of the Gen-Probe AMPLIFIED Chlamydia trachomatis assay in detecting Chlamydia trachomatis in endocervical and urine specimens in women and urethral and urine specimens from men attending sexually transmitted disease and family planning clinics. J Clin Microbiol 1998;36:3230-3.
15. Lauderdale T-L, Landers L, Thomeycroft I, Chapin K. Comparison of the PACE-2 assay, two amplification assays and clearview EIA for detection of Chlamydia trachomatis in female endocervical and urine specimens. J Clin Microbiol 1999;37:2223-9.
16. Black CM. "But Doctor, I'm Celibate" The potential for, sources and implications of false-positive (and negative) results for tests for Chlamydia trachomatis. Clin Microbiol News 1998;20:120-4.
17. Alberta Health. Sexually Transmitted Diseases in Alberta. Epidemiologic Report to December 1997 Health Surveillance Branch, Alberta Health and Wellness, Edmonton, Alberta, 1998.
18. Mahony JB, Luinstra KE, Sellors JW, et al. Role of confirmatory PCRs in determining performance of Chlamydia Amplicor PCR with endocervical samples from women with a low prevalence of infection. J Clin Microbiol 1994;32:2490-3.
19. Skulnick M, Chua R, Simor AE, et al. Use of the polymerase chain reaction for the detection of Chlamydia trachomatis from endocervical and urine specimens in an asymptomatic low- prevalence population of women. Diagn Microbiol Infect Dis 1994;20:195-201.
20. Dean D, Ferrero D, McCarthy M. Comparison of performance and cost-effectiveness of direct fluorescent-antibody, ligase chain reaction, and PCR assays for verification of chlamydial enzyme immunoassay results for population with a low to moderate prevalence of Chlamydia trachomatis infection. J Clin Microbiol 1998;36:94-9.
21. Masse R, Laperriere H, Rousseau H, Lefebvre J, Remis RS. Chlamydia trachomatis cervical infection: prevalence and determinants among women presenting for routine gynecologic examinations. CMAJ 1991;145:953-61.
22. Howell MR, Quinn TC, Graydos CA. Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics. A cost-effectiveness analysis of three strategies. Ann Intern Med 1998;128:277-84.
23. Mosure DJ, Berman S, Kleinbaum D, Halloran ME. Predictors of Chlamydia trachomatis infection among female adolescents: A longitudinal analysis. Am J Epidemiol 1996;144:997-1003.
24. Gerc M, Mardh P-A. A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women. Ann Int Med 1996;124(1 pt 1):1-7.
25. Miller WC. Screening for chlamydial infection. A model program based on prevalence. Sex Trans Dis 1998;25:201-10.